• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BECTON, DICKINSON & CO. (SPARKS) BD BBL¿ TRYPTICASE¿ SOY BROTH; CULTURE MEDIA, NON-SELECTIVE AND NON-DIFFERENTIAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BECTON, DICKINSON & CO. (SPARKS) BD BBL¿ TRYPTICASE¿ SOY BROTH; CULTURE MEDIA, NON-SELECTIVE AND NON-DIFFERENTIAL Back to Search Results
Model Number 297354
Medical Device Problem Code Incorrect, Inadequate or Imprecise Result or Readings (1535)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 12/07/2022
Type of Reportable Event Malfunction
Event or Problem Description
It was reported that bd bbl¿ trypticase¿ soy broth have microbial contaminated tubes.The following information was provided by the initial reporter: customer reports about 200 tubes (2pk) are contaminated.
 
Additional Manufacturer Narrative
Device evaluated by mfr: a device evaluation and/or device history review is anticipated but is not complete.Upon completion, a supplemental report will be filed.
 
Event or Problem Description
It was reported that bd bbl¿ trypticase¿ soy broth have microbial contaminated tubes.The following information was provided by the initial reporter: customer reports about 200 tubes (2pk) are contaminated.
 
Additional Manufacturer Narrative
H.6 investigation summary: material 297354 is manufactured by rehydrating the media components with usp purified water, and thoroughly mixing until a homogeneous solution is obtained.The tubes are filled, capped, torqued and then labeled by machine per standard operating procedure (sop).The tubes are terminally autoclaved in an air over pressure (aop) autoclave, per manufacturing instructions, using a validated cycle.Post autoclaving, tubes are packaged into final shipping configurations.The batch history record reviews for batch 2062203 was satisfactory and no quality notifications were generated during manufacturing and inspection.In process checks are performed during manufacturing at designated intervals per procedures.Those checks confirmed that the caps were tightened to the validated specifications per internal procedure and fill volumes were within specification.Qc inspection and testing were satisfactory at time of release.As part of the release criteria for this product the bhrs are reviewed to confirm the following: the total elapsed time between end of formulation and start of the autoclave cycle was within the specified limits.All autoclave parameters conformed to the validated cycle parameters for this product.The minimum f0 for this product was met.The complaint history was reviewed, and other complaints have been taken on this batch for contamination for non-viable organisms.Retention samples from batch 2062203 (10 tubes) were available for inspection.No media defects such as turbid media or sedimentation were observed in 10/10 retention samples from visual inspection.For investigation of the complaint, retention samples were tested.Retention tubes were incubated at 20 to 25 degrees c (1 tube) and 33 to 37 degrees c (1 tube).At seven days incubation, tubes were inspected and neither retention tube had microbial growth or change in media appearance.Two photos were received to assist with the investigation: both photos show two tubes from batch 2062203.The media in both tubes does appear to be turbid/contaminated.No returns were received to assist with the investigation.This media is terminally autoclaved after formulation and filling to reduce bioburden but does not have a sterile claim.Product should not be used if medium shows evidence of contamination, discoloration, drying, or other signs of deterioration.This complaint can be confirmed for contamination based on the evidence provided by the photos received.Bd will continue to trend complaints for contamination/non-viable organisms.No additional actions are indicated at this time.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
BD BBL¿ TRYPTICASE¿ SOY BROTH
Common Device Name
CULTURE MEDIA, NON-SELECTIVE AND NON-DIFFERENTIAL
Manufacturer (Section D)
BECTON, DICKINSON & CO. (SPARKS)
7 loveton circle
sparks MD 21152
Manufacturer (Section G)
BECTON, DICKINSON & CO. (SPARKS)
7 loveton circle
sparks MD 21152
Manufacturer Contact
phillip emmert
9450 south state street
sandy, UT 84070
8015296192
MDR Report Key15991947
Report Number1119779-2022-01496
Device Sequence Number6103548
Product Code JSG
UDI-Device Identifier30382902973547
UDI-Public30382902973547
Combination Product (Y/N)N
Initial Reporter CountryCA
PMA/510(K) Number
NA
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Other,Foreign,User Facility
Initial Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date (Section B) 01/25/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Other
Device Model Number297354
Device Catalogue Number297354
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 12/07/2022
Supplement Date Received by Manufacturer01/25/2023
Initial Report FDA Received Date12/15/2022
Supplement Report FDA Received Date01/29/2023
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Is the Device Labeled for Single Use? (Y/N) No
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient SexUnknown
-
-